6-溴-5-甲基-3H-咪唑并[4,5-b]吡啶 | 28279-41-6

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 中文名称: 6-溴-5-甲基-3H-咪唑并[4,5-b]吡啶
• 中文别名: 6-溴-5-甲基-3H-咪唑[4,5-B]并吡啶
• 英文名称: 6-bromo-5-methyl-3H-imidazo[4,5-b]pyridine
• 英文别名: 6-bromo-5-methylimidazo[4,5-b]pyridine；6-bromo-5-methyl-1(3)H-imidazo[4,5-b]pyridine；6-bromo-5-methyl-1H-imidazo[4,5-b]pyridine；5-Methyl-6-brom-4-aza-benzimidazol
• CAS: 28279-41-6
• 化学式: C₇H₆BrN₃
• mdl: MFCD00184166
• 分子量: 212.049
• InChiKey: ZZFKQUTYXXPQBS-UHFFFAOYSA-N

物化性质

• 沸点：
  230.6±50.0 °C(Predicted)
• 密度：
  1.86±0.1 g/cm3(Predicted)
• 溶解度：
  可溶于氯仿（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 6-Bromo-5-methyl-3h-imidazo[4,5-b]pyridine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 6-Bromo-5-methyl-3h-imidazo[4,5-b]pyridine
CAS number: 28279-41-6

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H6BrN3
Molecular weight: 212

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  6-溴-5-甲基-3H-咪唑并[4,5-b]吡啶 在 sodium hydroxide 、 palladium on activated charcoal 、 铂 作用下， 生成 5-甲基-1H-咪唑并[4,5-b]吡啶
  参考文献：
  名称：

  Graboyes; Day, Journal of the American Chemical Society, 1957, vol. 79, p. 6421,6423,6424

  摘要：

  DOI：
• 作为产物：
  描述：

  2-氨基-6-甲基吡啶 在 硫酸 、 溴 、 硝酸 、 sodium acetate 、 一水合肼 、 溶剂黄146 、 锌 作用下， 以 正丁醇 为溶剂， 反应 5.0h， 生成 6-溴-5-甲基-3H-咪唑并[4,5-b]吡啶
  参考文献：
  名称：

  Improvement of the Synthesis of 6-Bromo-5-methylimidazo[4,5-b]pyridine, a Stabilizer for Color Photography

  摘要：

  提出了制备 6-溴-5-甲基咪唑并[4,5-b]吡啶的方法，这是一种用于稳定 TsMF-2 彩色感光胶片的稳定剂，也是感光套装显影膏的一种成分。

  DOI：

  10.1007/s11167-005-0392-y

文献信息

• NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS
  申请人：Diaz Caroline Jean

  公开号：US20100222345A1

  公开（公告）日：2010-09-02

  This invention relates to novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy.

  这项发明涉及新型化合物，它们是阿片受体的拮抗剂或逆向激动剂之一，以及含有它们的药物组合物，它们的制备过程，以及它们在治疗中的应用。
• [EN] SUBSTITUTED-1,4-DIHYDROPYRAZOLO[4,3-b]INDOLES<br/>[FR] DIHYDROPYRAZOLO[4,3-B]INDOLES SUBSTITUÉES DANS LES POSITIONS 1 ET 4
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2014039831A1

  公开（公告）日：2014-03-13

  Disclosed are compounds of Formula (1), and pharmaceutically acceptable salts thereof, wherein L, R1, R2, R3, R4, R5, R6, and R7 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating obesity and related diseases, disorders, and conditions associated with MetAP2.

  本公开涉及式（1）的化合物及其药用盐，其中L、R1、R2、R3、R4、R5、R6和R7在规范中定义。本公开还涉及制备式1化合物的材料和方法，含有它们的药物组合物，以及它们用于治疗与MetAP2相关的肥胖和相关疾病、紊乱和病况的用途。
• Halogenation of 2-Unsubstituted and 2-Methylimidazo[4,5-b]pyridine Derivatives
  作者：Yu. M. Yutilov、Kh. Ya. Lopatinskaya、N. N. Smolyar、S. V. Gres’ko

  DOI：10.1007/s11178-005-0186-y

  日期：2005.3

  Halogenation of 2-unsubstituted and 2-methylimidazo[4,5-b]pyridines and their N-methyl derivatives with bromine and chlorine in acetic acid takes different pathways, depending on the acetic acid concentration. The bromination in 50% aqueous acetic acid gives only 6-bromoimidazo[4,5-b]pyridines; bromination and chlorination of 2-unsubstituted imidazo[4,5-b]pyridines in glacial acetic acid leads to 5,6-dibromo(dichloro)imidazo[4,5-b]pyridin-2-ones, and bromination of 2-methylimidazo[4,5-b]pyridines in glacial acetic acid involves both the pyridine ring and the 2-methyl group to afford the corresponding 6-bromo-2-tribromomethylimidazo[4,5-b]pyridines.

  在乙酸中用溴和氯对 2-未取代的和 2-甲基咪唑并[4,5-b]吡啶及其 N-甲基衍生物进行卤化，根据乙酸浓度的不同，卤化途径也不同。在 50% 的乙酸水溶液中进行溴化反应只能得到 6-溴咪唑并[4,5-b]吡啶；在冰醋酸中对 2-未取代的咪唑并[4,5-b]吡啶进行溴化和氯化反应，可生成 5,6-二溴（二氯）咪唑并[4,5-b]吡啶-2-酮；在冰醋酸中对 2-甲基咪唑并[4,5-b]吡啶进行溴化反应，可生成 2-甲基咪唑并[4,5-b]吡啶-2-酮、2-甲基咪唑并[4,5-b]吡啶在冰乙酸中的溴化反应涉及吡啶环和 2-甲基，从而得到相应的 6-溴-2-三溴甲基咪唑并[4,5-b]吡啶。
• Heterocyclic inhibitors of MEK and methods of use thereof
  申请人：Wallace Eli

  公开号：US20050153942A1

  公开（公告）日：2005-07-14

  Disclosed are compounds of the Formula I and pharmaceutically acceptable salts and prodrugs thereof, wherein R 1 , R 2 , R 7 , R 8 and R 9 , W, X, Y and Z are as defined in the specification. Such compounds are MEK inhibitors and are useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals, and inflammatory conditions. Also disclosed are methods of using such compounds in the treatment of hyperproliferative diseases in mammals and pharmaceutical compositions containing such compounds.

  本发明涉及公式I的化合物及其药学上可接受的盐和前药，其中R1、R2、R7、R8和R9、W、X、Y和Z如规范中所定义。这些化合物是MEK抑制剂，可用于治疗哺乳动物的增殖过度疾病，如癌症和炎症，以及炎症病症。本发明还涉及使用这些化合物治疗哺乳动物的增殖过度疾病的方法和含有这些化合物的制药组合物。
• Inhibitors of MEK
  申请人：Vernier Jean-Michel

  公开号：US20080255133A1

  公开（公告）日：2008-10-16

  This invention concerns to N-(2-aylamino)aryl sulfonamides, which are inhibitors of MEK, methods of using such compounds in the treatment of hyperproliferative diseases, and to pharmaceutical compositions containing such compounds.

  本发明涉及N-(2-烷基氨基)芳基磺酰胺，其为MEK抑制剂，以及使用这些化合物治疗过度增生性疾病的方法，以及含有这些化合物的制药组合物。